Medical AI Alliance
← Company Index
Biotech & Drug DiscoveryKOSPI 007570383 approvals44 trials

ILYANG PHARMACEUTICAL CO.,LTD

Official website

KOSPI-listed pharmaceutical company known for its anti-ulcer drug Noltec and leukemia treatment Supect (radotinib).

Price

Change

Market cap

Business overview

Source: DART corporate disclosure

Founded in 1946 and listed on KOSPI in 1974, Ilyang Pharmaceutical is a diversified pharmaceutical company. Its main products are Noltec, Korea's 14th approved new drug, an anti-ulcer treatment for gastric ulcer and GERD, and Supect (radotinib), Korea's 18th approved new drug, a CML leukemia treatment approved as a first-line therapy in October 2015, alongside the P-CAB class gastric acid suppressant candidate IY-828026 and the quadrivalent influenza vaccine Theratect prefilled syringe. Its 55th-term consolidated revenue was KRW 272.4 billion, with operating profit of KRW 4.9 billion and net income of KRW 7.1 billion, and Supect was out-licensed to China's Yangzhou Ilyang Pharmaceutical Co., Ltd. in 2013, completing local Phase 3 trials and an NDA filing.

Products & technology

  • NoltecAnti-ulcer drug for duodenal/gastric ulcer, GERD, and H. pylori eradication therapy
  • Noltec PlusNoltec-antacid combination formulation
  • Supect (radotinib)Leukemia (CML) treatment
  • Theratect prefilled syringeQuadrivalent influenza vaccine
  • Ilyang Flu Vaccine prefilled syringeTrivalent influenza vaccine

Regulatory approvals

data.go.kr

376 Korean MFDS drug approvals · 1966–2026 / 7 Korean MFDS device approvals · 1997–2016

  • MFDS drugvopcab tab. 10mg2026-08-24
    Drug · Prescription · Approval202602451
  • MFDS drugvopcab Tab. 20mg2026-08-24
    Drug · Prescription · Approval202602452
  • MFDS drugCrego Duo ODT 10/5mg2026-06-30
    Drug · Prescription · Approval202601876
  • MFDS drugCrego Duo ODT 10/10mg2026-06-30
    Drug · Prescription · Approval202601877
  • MFDS drugCrego Duo ODT 10/20mg2026-06-30
    Drug · Prescription · Approval202601878
  • MFDS drugMagric Calcon Speed Solution2026-05-27
    Drug · OTC · Notification202601535
  • MFDS drugIlyang Famotidine Tab.2026-05-08
    Drug · OTC · Notification202601351
  • MFDS drugBurmooden S Gel2026-04-20
    Drug · OTC · Notification202601137
  • MFDS drugSokco zero cap.2026-04-15
    Drug · OTC · Notification202601088
  • MFDS drugTriplelow Tab 40/5/12.5mg2026-04-08
    Drug · Prescription · Approval202600996
  • MFDS drugTriplelow Tab 80/5/25mg2026-04-08
    Drug · Prescription · Approval202600997
  • MFDS drugTriplelow Tab 80/5/12.5mg2026-04-08
    Drug · Prescription · Approval202600998
Show 68 more
  • MFDS drugIL-YANG KiWhang Solution2026-03-20
    Drug · OTC · Notification202600803
  • MFDS drugIlyang Vita Won Sol.2026-02-19
    Drug · OTC · Notification202600442
  • MFDS drugIL-YANG WONBI Oral Liquid2026-01-28
    Drug · OTC · Approval202600235
  • MFDS drugIL-YANG WON Oral Liquid2026-01-28
    Drug · OTC · Approval202600236
  • MFDS drugIlyang Mag Z tab.2025-12-22
    Drug · OTC · Notification202503336
  • MFDS drugCleanTokTokB Nasal Spray2025-11-10
    Drug · OTC · Notification202502900
  • MFDS drugAlled Zero Tab. 180mg2025-10-17
    Drug · Prescription · Approval202502697
  • MFDS drugWonbi-D S Sol.2025-09-01
    Drug · OTC · Notification202502291
  • MFDS drugLactodearophen Tab2025-08-05
    Drug · OTC · Notification202502036
  • MFDS drugWizero Alfa Powder2025-06-19
    Drug · OTC · Notification202501520
  • MFDS drugIlyang Three Sok Tab.2025-04-30
    Drug · OTC · Notification202501043
  • MFDS drugJoinup double Plaster2025-04-15
    Drug · OTC · Notification202500910
  • MFDS drugNOLTEC PLUS Tab. 20/500mg2025-03-04
    Drug · Prescription · Approval202500485
  • MFDS drugNuneTop F Soft Cap.2025-02-28
    Drug · OTC · Notification202500464
  • MFDS drugAlled Zero Tab. 120mg2025-02-07
    Drug · OTC · Notification202500268
  • MFDS drugWizero Yukwae Soft Ext.2024-11-19
    Drug · OTC · Notification202402724
  • MFDS drugpamixbio Ginkgo Tab.2024-11-06
    Drug · OTC · Notification202402625
  • MFDS drugMeco Mg Premium Tab.2024-10-23
    Drug · OTC · Notification202402513
  • MFDS drugTitano A Ointment2024-08-27
    Drug · OTC · Notification202402067
  • MFDS drugAzinpamK Tab.2024-05-31
    Drug · OTC · Notification202401358
  • MFDS drugMeco Mg Premium Tab.Revoked2024-05-27
    Drug · OTC · Notification202401289
  • MFDS drugMian Toktok Eye Drops2024-04-29
    Drug · OTC · Notification202401031
  • MFDS drugJang Zero Q Enteric Coated Tab.2024-03-29
    Drug · OTC · Notification202400705
  • MFDS drugFreenose S Tab.2024-03-26
    Drug · OTC · Notification202400648
  • MFDS drugChroazone N Tab.2024-03-26
    Drug · OTC · Notification202400654
  • MFDS drugJang Zero S Granule2024-03-21
    Drug · OTC · Notification202400585
  • MFDS drugIlyang Care Nail Lacquer2024-03-14
    Drug · OTC · Notification202400541
  • MFDS drugAzinpamQ Tab.2024-02-22
    Drug · OTC · Notification202400385
  • MFDS drugTwoB-Beta Sol.2024-02-14
    Drug · OTC · Notification202400325
  • MFDS drugMulti Sok Tab.2024-01-23
    Drug · OTC · Notification202400177
  • MFDS drugWonbi-D Gold Sol.Revoked2024-01-04
    Drug · OTC · Notification202400029
  • MFDS drugTERATECT Vaccine INJ.2024-01-04
    Drug · Prescription · Approval202400021
  • MFDS drugCaneclo Vagina. Tab.2023-12-05
    Drug · OTC · Notification202303278
  • MFDS drugSpamac S Tab.2023-11-16
    Drug · OTC · Notification202303159
  • MFDS drugBonaling speed sol.2023-10-04
    Drug · OTC · Notification202302853
  • MFDS drugBenfovitanice Tab.2023-09-06
    Drug · OTC · Notification202302654
  • MFDS drugCoQ10 Vitaalbu X tab.2023-08-30
    Drug · OTC · Notification202302576
  • MFDS drugIdiance Duo Tab. 12.5/1000mg2023-08-30
    Drug · Prescription · Approval202302577
  • MFDS drugIdiance Duo Tab. 12.5/850mg2023-08-30
    Drug · Prescription · Approval202302578
  • MFDS drugIdiance Duo Tab. 12.5/500mg2023-08-30
    Drug · Prescription · Approval202302579
  • MFDS drugCoQ10 Vitaalbu X tab.Revoked2023-07-19
    Drug · OTC · Notification202302187
  • MFDS drugDiochimin Tab.(Diosmin)2023-07-03
    Drug · OTC · Notification202302041
  • MFDS drugDapaige ER Tab. 10/500mg2023-06-21
    Drug · Prescription · Approval202301894
  • MFDS drugSokcol syrup2023-03-21
    Drug · OTC · Notification202300978
  • MFDS drugIlyang acetaminophen syrup2023-02-20
    Drug · OTC · Notification202300632
  • MFDS drugSpantec Sublingual Tab.(Phloroglucinol Hydrate)2023-01-26
    Drug · Prescription · Approval202300345
  • MFDS drugDapaige ER Tab. 10/1000mg2023-01-06
    Drug · Prescription · Approval202300144
  • MFDS drugSokcol cool Powder2022-11-28
    Drug · OTC · Notification202204271
  • MFDS drugIlyang Dapame XR Tab. 5/500mg2022-11-10
    Drug · Prescription · Approval202204067
  • MFDS drugIlyang Dapame XR Tab. 10/500mgRevoked2022-11-10
    Drug · Prescription · Approval202204068
  • MFDS drugIlyang Chungshim Sol.2022-10-19
    Drug · OTC · Notification202203867
  • MFDS drugIlyang Galgeuntang Sol.2022-07-20
    Drug · OTC · Notification202202997
  • MFDS drugIlyang Socheongryongtang Sol.2022-07-20
    Drug · OTC · Notification202202998
  • MFDS drugIlyang Samsoeum Sol.2022-07-19
    Drug · OTC · Notification202202970
  • MFDS drugIlyang Ssangwhatang Sol.2022-07-19
    Drug · OTC · Notification202202971
  • MFDS drugWizero alfa Tab.2022-07-15
    Drug · OTC · Notification202202909
  • MFDS drugtoamin inj. 3%2022-06-08
    Drug · Prescription · Notification202202374
  • MFDS drugDodamdodam Triple Vita Sol.2022-04-26
    Drug · OTC · Notification202201698
  • MFDS drugIdiance Duo Tab. 5/850mg2022-04-04
    Drug · Prescription · Approval202201336
  • MFDS drugIdiance Duo Tab. 5/500mg2022-04-04
    Drug · Prescription · Approval202201337
  • MFDS drugIdiance Duo Tab. 5/1000mg2022-04-04
    Drug · Prescription · Approval202201338
  • MFDS drugCheongrohwan F Tab Ilyang.2022-03-21
    Drug · OTC · Notification202201117
  • MFDS drugIL-YANG Dapagliflozin tab. 5mg2022-03-02
    Drug · Prescription · Approval202200898
  • MFDS drugIL-YANG Dapagliflozin tab. 10mg2022-01-20
    Drug · Prescription · Approval202200328
  • MFDS drugJanuarin-duo Tab. 50/850mg2022-01-19
    Drug · Prescription · Approval202200304
  • MFDS drugJanuarin-duo Tab. 50/500mg2022-01-19
    Drug · Prescription · Approval202200305
  • MFDS drugJanuarin-duo Tab. 50/1000mg2022-01-19
    Drug · Prescription · Approval202200306
  • MFDS drugJanuga Tab. 10/100mg2022-01-04
    Drug · Prescription · Approval202200069

Showing the 80 most recent of 383 records.

Clinical trials

data.go.kr

44 MFDS clinical trial authorisations · 2012–2025 (Phase 1 22 · Phase 3 11 · Bioequivalence 10 · Phase 1/2a 1)

  • Phase 1IY-8280262025-12-29

    1 trial site

  • Phase 1IY-DDI20252025-09-12

    1 trial site

  • Phase 1IY-1149DO-T2024-11-29

    2 trial sites

  • Phase 1슈펙트캡슐(라도티닙염산염)2024-06-27

    2 trial sites

  • Phase 1IY-HCR212024-04-09

    2 trial sites

  • Phase 3놀텍정10mg(일라프라졸)2024-01-18

    13 trial sites

  • Phase 1IY-NS2502024-01-02

    2 trial sites

  • Phase 3일양플루백신4가주(인플루엔자분할백신)2023-12-21

    12 trial sites

  • Phase 1IY-1149DO-T2022-09-21

    2 trial sites

  • Phase 1놀텍정10mg(일라프라졸)2022-08-26

    1 trial site

  • Phase 1IY-1149DO-T2022-06-24

    2 trial sites

  • Phase 1IY-HCR212022-05-26

    2 trial sites

Show 32 more
  • Bioequivalence요시케어정10밀리그램(솔리페나신숙신산염)2022-04-07

    2 trial sites

  • Bioequivalence일양클로피도그렐정75밀리그램(클로피도그렐황산염)2021-12-14

    2 trial sites

  • Phase 1놀텍정10mg(일라프라졸)2021-10-28

    1 trial site

  • Phase 1IY-IC0622021-10-13

    2 trial sites

  • Phase 3일양플루백신4가주(인플루엔자분할백신)2020-03-03

    10 trial sites

  • Phase 1IYV70022020-02-28
  • Phase 1IY-HCR172018-09-04

    1 trial site

  • Phase 1IY-HCR172018-08-27

    1 trial site

  • Phase 3놀텍정10mg(일라프라졸)2018-02-20

    8 trial sites

  • Phase 3슈펙트캡슐(라도티닙염산염)2018-02-19

    22 trial sites

  • Phase 3일양플루백신4가주(인플루엔자분할백신)2017-06-21

    16 trial sites

  • Bioequivalence후릭스정(푸로세미드)2016-11-25

    2 trial sites

  • Phase 1놀텍정10mg(일라프라졸)2016-11-10

    1 trial site

  • Phase 1IYV70012016-10-26

    1 trial site

  • Bioequivalence일양디세텔정(피나베륨브롬화물)2016-10-19

    2 trial sites

  • Bioequivalence하이네콜정(베타네콜염화물)2016-10-17

    2 trial sites

  • Phase 3일양플루백신4가주(인플루엔자분할백신)2015-10-21

    16 trial sites

  • Bioequivalence플루렉스캡슐75밀리그램(인산오셀타미비르)2015-09-10

    2 trial sites

  • Bioequivalence일양레바미피드정2015-08-07

    2 trial sites

  • Phase 1/2a일양플루백신4가주(인플루엔자분할백신)2015-01-29

    1 trial site

  • Bioequivalence인다팜정(인다파미드)2014-02-05

    2 trial sites

  • Phase 3일양플루백신주(인플루엔자분할백신)2013-10-18

    13 trial sites

  • Bioequivalence일양로자탄플러스에프정2013-03-05

    2 trial sites

  • Phase 1일양플루백신주(인플루엔자분할백신)2013-01-24

    1 trial site

  • Phase 3일양플루백신주(인플루엔자분할백신)2012-11-22

    10 trial sites

  • Phase 1일양플루백신주(인플루엔자분할백신)2012-09-14

    1 trial site

  • Phase 3놀텍정10mg(일라프라졸)2012-09-03

    16 trial sites

  • Bioequivalence듀얼다운정10/160밀리그램2012-08-29

    2 trial sites

  • Phase 1놀텍정10mg(일라프라졸)2012-06-12
  • Phase 3놀텍정10mg(일라프라졸)2012-06-11

    13 trial sites

  • Phase 1놀텍정10mg(일라프라졸)2012-04-13

    1 trial site

  • Phase 1놀텍정10mg(일라프라졸)2012-04-12

    1 trial site

R&D and key agreements

Source: DART corporate disclosure

슈펙트(라도티닙) 2차치료제 적응증 · 만성골수성백혈병(CML) 2차치료제 · 다국가(4개국) 임상3상 진행중

슈펙트 파킨슨병 적응증 · 파킨슨병 · 프랑스 임상2상 진행중(IND승인 완료)

IY-828026 · 위산분비 관련질환 · 임상1상 진행중 · P-CAB class gastric acid suppressant candidate

비뇨기 복합제 개량신약 · 비뇨기질환 · 임상1상 진행중

놀텍 NSAIDs 병용 적응증 확대 · 임상1상 완료, 임상3상 진행중

Not yet compiled: business overview. Send us materials and we will add them

Companies approved for the same productsBiotech & Drug Discovery

Ranked by how many MFDS product categories overlap. Not a ranking — a pointer to where to look.

OSANG HEALTHCARE CO.,LTD.2 shared

Founded 1996, listed on KOSDAQ in 2024, OSANG HEALTHCARE develops and sells biochemistry, immunodiagnostic, and molecular IVD products.

Aprogen Biologics Inc.1 shared

Aprogen Biologics develops Remicade, Rituxan, and Herceptin biosimilars and operates a world top-5 scale antibody production facility.

CALTH. Inc1 shared

Holds manufacturing approvals for 42 point-of-care diagnostic reagents and devices in the IVD market.

ChoA Pharmaceutical Co., LTD.1 shared

Founded in 1996 and listed on KOSDAQ in 1999, ChoA Pharmaceutical is an OTC-focused drugmaker exporting to 23 countries worldwide.

DONG-A ST CO.,LTD1 shared

Dong-A ST, spun off from Dong-A Socio Holdings in 2013 and KOSPI-listed, makes prescription drugs like Growtropin, Stillen, and Bacchus.

DongKookPharmaceuticalCo.,Ltd.1 shared

KOSDAQ-listed comprehensive healthcare and pharmaceutical company behind the gum treatment Insadol and the wound-care ointment Madecassol.

Hanmi Pharm. Co., Ltd.1 shared

KOSPI-listed pharmaceutical company behind the combination drugs Amosartan (hypertension) and Rosuzet (dyslipidemia).

IL DONG PHARMACEUTICAL CO., LTD.1 shared

Founded and listed on the KOSPI in 2016, Il Dong Pharmaceutical manufactures products including the Aronamin vitamin line.

KOREAN DRUG CO., LTD.1 shared

Founded in 1980, Korean Drug produces the cold medicine Haben and the dementia drug Neuromed, along with other CNS disease treatments.

KYUNG NAM PHARM.CO.,LTD.1 shared

Founded in 1998, Kyungnam Pharm is a pharmaceutical and health-food company known for the vitamin brand Lemona and placenta drink Jahasaengryeok.

SD BIOSENSOR INC.1 shared

KOSPI-listed in-vitro diagnostics company known for the STANDARD Q antigen/antibody test kits.

SINSIN PHARMACEUTICAL Co., LTD.1 shared

Sinsin Pharmaceutical sells medicated patches and OTC medicines through direct deals with over 13,000 pharmacies nationwide.

Sources and updates

Company basics
Korea Exchange · DART
Business content
Compiled from disclosure filings
AI visibility
Measured 2026-08-13

This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.

Request a correction or addition